Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 2,690 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 2,690 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $45.00, for a total transaction of $121,050.00. Following the completion of the sale, the director owned 12,546 shares in the company, valued at approximately $564,570. The trade was a 17.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Kiniksa Pharmaceuticals International Trading Down 0.6%

NASDAQ:KNSA traded down $0.27 on Thursday, hitting $44.71. The company had a trading volume of 312,322 shares, compared to its average volume of 626,418. Kiniksa Pharmaceuticals International, plc has a 52 week low of $18.25 and a 52 week high of $45.50. The stock has a market capitalization of $3.39 billion, a price-to-earnings ratio of 99.36 and a beta of 0.06. The firm has a 50 day moving average of $42.06 and a two-hundred day moving average of $38.68.

Analyst Upgrades and Downgrades

Several equities analysts have commented on KNSA shares. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Finally, The Goldman Sachs Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.33.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Savant Capital LLC bought a new stake in Kiniksa Pharmaceuticals International in the second quarter worth approximately $398,000. Essex Investment Management Co. LLC grew its position in shares of Kiniksa Pharmaceuticals International by 44.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 247,301 shares of the company’s stock worth $9,603,000 after buying an additional 75,864 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $1,648,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at $1,480,000. Finally, Franklin Resources Inc. lifted its position in shares of Kiniksa Pharmaceuticals International by 62.2% during the 2nd quarter. Franklin Resources Inc. now owns 108,574 shares of the company’s stock valued at $3,004,000 after acquiring an additional 41,632 shares during the period. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.